<DOC>
	<DOC>NCT00594984</DOC>
	<brief_summary>Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC) Part 2: To compare median duration of progression free survival (PFS)</brief_summary>
	<brief_title>Phase I/II Combination With Irinotecan- Erbitux</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Biopsy proven MCRC Prior irinotecan allowed Prior Erbitux allowed No prior brivanib No prior combination of irinotecan with Erbitux No secondary malignancies No anticoagulation therapy No prior history of blood clots requiring anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>